©2024 Stanford Medicine
The clonoSEQ® Watch Registry
Recruiting
Trial ID: NCT04545333
Purpose
This is a prospective, multicenter, observational study of adult patients with a diagnosis of
acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia
(CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50
sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in
the management of lymphoid malignancies.
Official Title
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Stanford Investigator(s)
Lori Muffly
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
1. Patients must be able to provide written informed consent
2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of
routine clinical care
3. Age ≥ 18 years;
4. Documented hematologic malignancy (any of the below):
1. MM
2. ALL (B and T-cell subtypes)
3. B-cell NHL (all sub types)
4. CLL
5. Other lymphoid malignancies (upon review and approval by study chair)
Exclusion Criteria:
Patients must not meet any of the following criteria in order to be enrolled into the
study:
1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are
dictated per protocol
2. A decision has been made by the treating provider to not use the clonoSEQ Assay as
part of routine clinical care
Intervention(s):
diagnostic test: clonoSEQ Assay
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell